论文部分内容阅读
目的观察参麦注射液联合CAG方案治疗老年急性髓系白血病(AML)的临床疗效及不良反应。方法 42例初治老年AML患者随机分为两组。联合治疗组(20例)以参麦注射液联合CAG方案治疗;对照组(22例)则仅采用CAG方案治疗。结果两组治疗总有效率分别为65.0%和59.1%,差异无统计学意义(P>0.05);两组患者治疗后红细胞、白细胞、血红蛋白和血小板等均明显下降(P<0.05),而对照组治疗后下降更为明显(P<0.05);两组不良反应发生率分别为45.0%和63.6%,两组比较差异有统计学意义(P<0.05)。结论参麦注射液联合CAG方案治疗老年急性髓系白血病具有缓解骨髓抑制,减轻不良反应的作用,值得在临床推广。
Objective To observe the clinical efficacy and adverse reactions of Shenmai injection combined with CAG regimen in the treatment of senile acute myeloid leukemia (AML). Methods 42 cases of newly diagnosed AML patients were randomly divided into two groups. The combination therapy group (20 cases) was treated with Shenmai injection combined with CAG regimen; the control group (22 cases) only treated with CAG regimen. Results The total effective rates of the two groups were 65.0% and 59.1%, respectively, with no significant difference (P> 0.05). The levels of erythrocyte, leucocyte, hemoglobin and platelet in the two groups were significantly decreased (P <0.05) (P <0.05). The incidence of adverse reactions in both groups were 45.0% and 63.6%, respectively, with significant difference between the two groups (P <0.05). Conclusion Shenmai injection combined with CAG regimen in the treatment of acute myeloid leukemia in elderly patients has the effect of relieving bone marrow suppression and alleviating adverse reactions and is worthy of clinical promotion.